Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Taldefgrobep alfa (BHV-2000) in Obesity. The expected timing is based on the latest available company guidance and may change.
5/12/25- Initiate Ph2 study in H1 2025. 11/10/25:- Phase 2 obesity trial initiation now planned for Q4 2025; program prioritized for investment. 01/12/26:- Obesity Ph2 proof-of-concept trial initiated in Q4 2025; topline results in 2026. 03/02/26:- Obesity Phase 2 autoinjector trial ongoing; topline taldefgrobep weight-loss results now expected in H2 2026. 03/19/26:- Phase 2 obesity PoC (NCT07281495) fully enrolled; topline data expected in H2 2026. 05/04/26:- Obesity Phase 2 taldefgrobep study completed enrollment in Q1 2026; topline results remain expected in 2H 2026. 08/10/26:- Obesity enrollment completion and 2H 2026 topline timing were reiterated.
Verification
Confirm timing and program details against the company announcement or filing.